On May 22, 2026, Mizuho initiated coverage of Q32 Bio (NasdaqCM: QTTB) with an “Outperform” recommendation, projecting a 206.00% upside. The average one-year price target for Q32 Bio is $16.83 per share, ranging from a low of $13.13 to a high of $21.00, compared to its latest closing price of $5.50 per share.
Projected annual revenue for Q32 Bio is estimated at $2 million, reflecting a decline of 96.20%. The projected annual non-GAAP Earnings Per Share (EPS) stands at -$11.92. Institutional ownership has seen a decrease of 12 funds or 17.14% over the last quarter, with total shares owned increasing by 22.04% to 9.7 million shares.
Major shareholders include Orbimed Advisors with 2.25 million shares (13.29% ownership) and Atlas Venture Life Science Advisors with 2.09 million shares (12.34% ownership). Opaleye Management reported an increase of 83.02%, now holding 1.26 million shares (7.41% ownership).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
